756 related articles for article (PubMed ID: 9876028)
21. LH and non-SHBG testosterone and estradiol levels during testosterone replacement of hypogonadal men: further evidence that steroid negative feedback increases as men grow older.
Winters SJ; Wang C;
J Androl; 2010; 31(3):281-7. PubMed ID: 19959827
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study.
Wang C; Berman N; Longstreth JA; Chuapoco B; Hull L; Steiner B; Faulkner S; Dudley RE; Swerdloff RS
J Clin Endocrinol Metab; 2000 Mar; 85(3):964-9. PubMed ID: 10720024
[TBL] [Abstract][Full Text] [Related]
23. The role of long-acting parenteral testosterone undecanoate compound in the induction of secondary sexual characteristics in males with hypogonadotropic hypogonadism.
Giagulli VA; Triggiani V; Carbone MD; Corona G; Tafaro E; Licchelli B; Guastamacchia E
J Sex Med; 2011 Dec; 8(12):3471-8. PubMed ID: 21995803
[TBL] [Abstract][Full Text] [Related]
24. Testosterone supplementation: what and how to give.
Jockenhövel F
Aging Male; 2003 Sep; 6(3):200-6. PubMed ID: 14628500
[TBL] [Abstract][Full Text] [Related]
25. A biodegradable testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10-11 weeks in hypogonadal men.
Bhasin S; Swerdloff RS; Steiner B; Peterson MA; Meridores T; Galmirini M; Pandian MR; Goldberg R; Berman N
J Clin Endocrinol Metab; 1992 Jan; 74(1):75-83. PubMed ID: 1727832
[TBL] [Abstract][Full Text] [Related]
26. Testosterone and gonadotropin levels in men with dementia.
Hogervorst E; Combrinck M; Smith AD
Neuro Endocrinol Lett; 2003; 24(3-4):203-8. PubMed ID: 14523358
[TBL] [Abstract][Full Text] [Related]
27. NTP Toxicology and Carcinogenesis Studies of 4,4'-Thiobis(6- t -butyl- m -cresol) (CAS No. 96-69-5) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1994 Dec; 435():1-288. PubMed ID: 12595928
[TBL] [Abstract][Full Text] [Related]
28. Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men.
Meikle AW; Mazer NA; Moellmer JF; Stringham JD; Tolman KG; Sanders SW; Odell WD
J Clin Endocrinol Metab; 1992 Mar; 74(3):623-8. PubMed ID: 1740497
[TBL] [Abstract][Full Text] [Related]
29. Transdermal testosterone gel: pharmacokinetics, efficacy of dosing and application site in hypogonadal men.
Meikle AW; Matthias D; Hoffman AR
BJU Int; 2004 Apr; 93(6):789-95. PubMed ID: 15049991
[TBL] [Abstract][Full Text] [Related]
30. Testosterone release from a subcutaneous, biodegradable microcapsule formulation (Viatrel) in hypogonadal men.
Amory JK; Anawalt BD; Blaskovich PD; Gilchriest J; Nuwayser ES; Matsumoto AM
J Androl; 2002; 23(1):84-91. PubMed ID: 11780927
[TBL] [Abstract][Full Text] [Related]
31. Which testosterone replacement therapy?
Cantrill JA; Dewis P; Large DM; Newman M; Anderson DC
Clin Endocrinol (Oxf); 1984 Aug; 21(2):97-107. PubMed ID: 6467640
[TBL] [Abstract][Full Text] [Related]
32. Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men.
Nieschlag E; Büchter D; Von Eckardstein S; Abshagen K; Simoni M; Behre HM
Clin Endocrinol (Oxf); 1999 Dec; 51(6):757-63. PubMed ID: 10619981
[TBL] [Abstract][Full Text] [Related]
33. Decline of serum levels of free testosterone in aging healthy Chinese men.
Li JY; Li XY; Li M; Zhang GK; Ma FL; Liu ZM; Zhang NY; Meng P
Aging Male; 2005; 8(3-4):203-6. PubMed ID: 16390747
[TBL] [Abstract][Full Text] [Related]
34. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men.
Swerdloff RS; Wang C; Cunningham G; Dobs A; Iranmanesh A; Matsumoto AM; Snyder PJ; Weber T; Longstreth J; Berman N
J Clin Endocrinol Metab; 2000 Dec; 85(12):4500-10. PubMed ID: 11134099
[TBL] [Abstract][Full Text] [Related]
35. Comparison of a new long-acting testosterone undecanoate formulation vs testosterone enanthate for intramuscular androgen therapy in male hypogonadism.
Minnemann T; Schubert M; Freude S; Hübler D; Gouni-Berthold I; Schumann C; Christoph A; Oettel M; Ernst M; Mellinger U; Krone W; Jockenhövel F
J Endocrinol Invest; 2008 Aug; 31(8):718-23. PubMed ID: 18852533
[TBL] [Abstract][Full Text] [Related]
36. Testosterone undecanoate in the treatment of male hypogonadism.
Edelstein D; Basaria S
Expert Opin Pharmacother; 2010 Aug; 11(12):2095-106. PubMed ID: 20642374
[TBL] [Abstract][Full Text] [Related]
37. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. II. Pharmacokinetics and pharmacodynamics of once weekly administration of testosterone enanthate.
Anderson RA; Wu FC
J Clin Endocrinol Metab; 1996 Mar; 81(3):896-901. PubMed ID: 8772547
[TBL] [Abstract][Full Text] [Related]
38. Reference intervals for serum sex hormones in Han Chinese adult men from the Fangchenggang Area Male Health and Examination Survey.
Qin X; Lv H; Mo Z; Chen Z; Lin L; Peng T; Zhang H; Yang X; Gao Y; Tan A; Huang S; Li H; Wu H; Deng Y; Li S
Clin Lab; 2012; 58(3-4):281-90. PubMed ID: 22582502
[TBL] [Abstract][Full Text] [Related]
39. Testosterone supplementation for hypogonadal men by the nasal route.
Mattern C; Hoffmann C; Morley JE; Badiu C
Aging Male; 2008 Dec; 11(4):171-8. PubMed ID: 19172548
[TBL] [Abstract][Full Text] [Related]
40. Injectable testosterone undecanoate has more favourable pharmacokinetics and pharmacodynamics than testosterone enanthate.
Partsch CJ; Weinbauer GF; Fang R; Nieschlag E
Eur J Endocrinol; 1995 Apr; 132(4):514-9. PubMed ID: 7711892
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
